Inhibition by retinoids of anthralin-induced mouse epidermal ornithine decarboxylase activity and anthralin-promoted skin tumor formation.
The retinoids all-trans-retinoic acid, 13-cis-retinoic acid, 4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1E- propen-1-yl]benzoic acid, 6-[1-(4-carboxyphenyl)-1E-propen-2-yl]-3,4-dihydro-4,4-dimethyl-2H -1-benzothiopyran, and 6-(5,6,7,8,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)- 2-naphthalenecarboxylic acid inhibited the induction of ornithine decarboxylase in CD-1 mouse epidermis treated with the weak tumor promoter anthralin (444 nmol). Enzyme activity reached maximal levels 48 h after the application of the promoter. This activity was most effectively inhibited when retinoids were applied to the epidermis 24 h after the promoter. These retinoids also inhibited the appearance of papillomas in mouse epidermis in the two-stage tumorigenesis model using 7,12-dimethylbenz(a)anthracene (200 nmol) as the initiator and anthralin (444 nmol) as the promoter during the 32-week period of promotion. Comparison of the doses of retinoids required to inhibit anthralin-induced ornithine decarboxylase by 50% and those required to inhibit anthralin-induced tumor promotion by 50% demonstrated that these values correlated.
Dawson
M I
MI
Life Sciences Division, SRI International, Menlo Park, California 94025.
Chao
W R
WR
Helmes
C T
CT
D000287:Administration, Topical; D000818:Animals; D000875:Anthralin / Q000037:antagonists & inhibitors*; D055598:Chemical Phenomena; D002621:Chemistry; D004790:Enzyme Induction / Q000187:drug effects; D004817:Epidermis / Q000201:enzymology*; D005260:Female; D051379:Mice; D009955:Ornithine Decarboxylase / Q000096:biosynthesis*; D010212:Papilloma / Q000139:chemically induced; D012176:Retinoids / Q000008:administration & dosage / Q000494:pharmacology*; D012878:Skin Neoplasms / Q000139:chemically induced*
D012176:Retinoids; D009955:Ornithine Decarboxylase; D000875:Anthralin